Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study

Table 2 Results from follow-up measurements

	ETN starters (n = 45)	ADA starters (n = 45)	Effect estimate for ETN vs. ADA (95% CI)	P-value
Improvement in VAS well-being compared to baseline, median (IQR)	2.0 (0.0 – 5.0)	2.0 (0.0 – 4.0)	0.89 (-0.01 – 1.78)^a	0.06
Decrease in active joint count compared to baseline, median (IQR)	3 (1 – 6)^b	2 (1 – 4)	-0.36 (-1.02 – 0.30)^a	0.28
Adverse events, n (%)	11 (24.4%)	15 (34.9%)^c	0.48 (0.16 – 1.44)^d	0.19
Uveitis events, n (%)	1 (2.2%)	0 (0.0%)	-	-

Missing values were handled by multiple imputation
ADA Adalimumab, ETN Etanercept, IQR Interquartile range, VAS Visual analogue scale
^amean difference as determined from linear mixed effects model
^bthere was one missing observation
^cthere were two missing observations
^dodds ratio as determined from logistic mixed effects model

ISSN: 1546-0096